The online version of this article (doi:10.1186/s12890-015-0085-0) contains supplementary material, which is available to authorized users.
The authors declare that they have no competing interests.
The authors report no potential conflicts of interest with any companies or organizations whose products or services are mentioned in this article.
KA and KN are responsible for the entire manuscript. KA, TT, NK, RT, and KN designed this study. TT and NK designed data base and performed statistical analysis. KA, SO, TT, TI, EY, MH, TA, KN, TN, HI, TH, and YI collected the patient’s data. KA, TT, NK, RT, and KN wrote this manuscript. All authors read and approved the final manuscript.
Although no report has demonstrated the efficacy of corticosteroid therapy for autoimmune pulmonary alveolar proteinosis (aPAP), we sometimes encounter patients who have received this therapy for various reasons. However, as corticosteroids can suppress alveolar macrophage function, corticosteroid therapy might worsen disease severity and increase the risk of infections.
For this retrospective cohort study, we sent a screening form to 165 institutions asking for information on aPAP patients treated with corticosteroids. Of the resulting 45 patients screened, 31 were enrolled in this study. We collected demographic data and information about corticosteroid treatment period, dose, disease severity score (DSS) over the treatment period, and complications.
DSS deteriorated during corticosteroid therapy in 23 cases (74.1 %) and the estimated overall cumulative worsening rate was 80.8 % for the total observation period. The worsening rate was significantly higher in patients treated with high-dose prednisolone (>18.9 mg/day, n = 16) than treated with low-dose prednisolone (≤18.9 mg/day, n = 15) divided by median daily dose (p < 0.02). Of patients with worsening, one died of disseminated aspergillosis and another of respiratory failure. Infections newly emerged in 6 cases during corticosteroid therapy (p < 0.05). Median serum granulocyte/macrophage colony-stimulating factor (GM-CSF) autoantibody levels were similar to previously reported data in a large cohort study.
The results demonstrate that corticosteroid therapy may worsen DSS of aPAP, increasing the risk for infections.
Additional file 1: Table S1. Disease severity score (DSS) for each case of pre- and post- start of the corticosteroids administration. (PDF 28 kb)12890_2015_85_MOESM1_ESM.pdf
Suzuki T, Sakagami T, Rubin BK, Nogee LM, Wood RE, Zimmerman SL, et al. Familial pulmonary alveolar proteinosis caused by mutations in CSF2RA. J Exp Med. 2008;205:1292–304. CrossRef
Gallin J, Goldstein L, Snyderman R. Inflammation: Basic principles and clinical correlates. 2nd ed. New York: Raven Press; 1992. p. 1–4.
Yamaguchi S, Takayanagi N, Tokunaga D, Sugita Y, Kawabata Y. A case of pulmonary alveolar proteinosis which initially deteriorated rapidly with worsening of pulmonary nocardiosis, responded promptly to treatment of the pulmonary nocardiosis. Nihon Kokyuki Gakkai Zasshi. 2010;48:580–3. PubMed
Morinari H, Terashi R, Okubo S, Homma S, Tanaka M. Remission of pulmonary alveolar proteinosis during antituberculous chemoadministration. Eur J Respir Dis. 1987;71:54–5. PubMed
- Outcome of corticosteroid administration in autoimmune pulmonary alveolar proteinosis: a retrospective cohort study
- BioMed Central
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II